OICR invests $1 million in the further development of two new cancer treatments - Canad... - 0 views
-
Assunta Krehl on 15 Mar 10Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) announced an investment of $1 million towards the development of two new promising cancer therapies. OncoTek Drug Delivery Inc (a subsidiary of Receptor Therapeutics) is one of the recipients.